Toxicity Testing Outsourcing Market Size, Share & Trends Analysis Report By Method (In Vitro, In Vivo), By GLP Type (GLP, Non GLP), By End-use, By Region, And Segment Forecasts, 2022 - 2030

Toxicity Testing Outsourcing Market Growth & Trends

The global toxicity testing outsourcing market size is expected to reach USD 6.78 billion by 2030, registering a CAGR of 9.4% from 2022 to 2030, according to a new report by Grand View Research, Inc. The increasing attrition rate in preclinical studies is stimulating demand for the outsourcing of preclinical studies to the CROs, which offer end-to-end services including toxicology testing services. Also, rising growth and innovation in pharmaceutical and biopharmaceutical companies, augment in R&D, and increasing ethical concerns about animal use are driving the enlargement of the market.

COVID-19 has significantly impacted the market for toxicity testing outsourcing. During the crisis, vaccine, medical device, and biologic contract research and manufacturing service providers played a predominant role in meeting the needs of pharmaceutical companies, biotech companies, and other end users. These organizations have been actively working towards the development of healthcare products that can be used as a treatment for patients, suffering from COVID-19 with mild symptoms, since the end of 2019. And these products require toxicity testing at each stage to assess safety and effectiveness, thus contributing to market growth.

Companies in the pharmaceutical and biopharmaceutical industries operate in an environment that is becoming more complex to understand. Improvements in many therapeutic areas, as well as the emergence of new types of therapies such as genetically targeted therapies, biologics, stem cell therapies, and other treatment modalities, have resulted in more complex development and regulatory pathways. To develop a treatment that is secure and efficient, it is necessary to do toxicity testing at each stage, which is boosting the market's growth.

Toxicity Testing Outsourcing Market Report Highlights

• The method segment is segmented into in vitro and in vivo. In vitro accounted for the largest market share of 57.7% in 2021
• The academic and research institutes segment is anticipated to grow at the fastest CAGR of 9.6% during the forecast period. This is due to the rising research on novel drugs intended for various therapeutic areas
• Asia Pacific accounted for the fastest CAGR of 11.3% during the forecast period, owing to the cost efficiency offered by CROs and CDMOs in countries such as India and China
• In February 2022, Charles River Laboratories International, Inc. announced an expansion of its manufacturing capacity in Brunt wood SciTech’s Alderley Park in Europe